Moody National Bank Trust Division Grows Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Moody National Bank Trust Division grew its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 20.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 73,226 shares of the medical research company’s stock after purchasing an additional 12,314 shares during the period. Moody National Bank Trust Division owned approximately 0.06% of NeoGenomics worth $1,207,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of NEO. Arizona State Retirement System boosted its holdings in NeoGenomics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company’s stock valued at $496,000 after acquiring an additional 708 shares during the period. Fernwood Investment Management LLC lifted its position in shares of NeoGenomics by 1.0% during the third quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock worth $1,320,000 after purchasing an additional 900 shares in the last quarter. FMR LLC boosted its stake in shares of NeoGenomics by 7.6% in the third quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 931 shares during the period. Blue Trust Inc. grew its holdings in shares of NeoGenomics by 42.3% in the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 987 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its stake in NeoGenomics by 3.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 32,505 shares of the medical research company’s stock worth $451,000 after buying an additional 1,030 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insiders Place Their Bets

In other news, General Counsel Alicia C. Olivo sold 5,175 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the transaction, the general counsel now directly owns 37,129 shares in the company, valued at approximately $570,301.44. This trade represents a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.30% of the company’s stock.

NeoGenomics Price Performance

NEO stock opened at $12.63 on Tuesday. The business has a 50 day moving average price of $16.79 and a 200 day moving average price of $15.67. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -20.70 and a beta of 1.24. NeoGenomics, Inc. has a fifty-two week low of $12.13 and a fifty-two week high of $19.11.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.04. The business had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The company’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.06) EPS. Equities research analysts anticipate that NeoGenomics, Inc. will post -0.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

NEO has been the subject of several recent research reports. Jefferies Financial Group initiated coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target for the company. Bank of America boosted their target price on NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Benchmark lowered NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Needham & Company LLC reissued a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, NeoGenomics currently has an average rating of “Moderate Buy” and a consensus target price of $20.30.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.